West Pharmaceutical Services, Inc. (NYSE: WST) reported third‑quarter 2025 results on October 23, 2025, posting net sales of $804.6 million, a 7.7% year‑over‑year increase and 5.0% organic growth. Adjusted earnings per share were $1.96, up from $1.85 in the same quarter last year, while diluted EPS rose to $1.92. The company’s operating cash flow reached $503.7 million, an 8.7% rise, and free cash flow climbed to $293.9 million, a 53.7% increase.
Proprietary Products generated $647.5 million in net sales, up 7.7% YoY and 5.1% organically, while Contract‑Manufactured Products delivered $157.1 million, an 8.0% YoY increase and 4.9% organic growth. Segment gross profit margins improved modestly, with Proprietary Products at 37.3% and Contract‑Manufactured at 16.1%. The company repurchased 552,593 shares for $134.0 million during the first nine months of 2025, underscoring its commitment to shareholder value.
Capital expenditures for the quarter were $209.8 million, down 22.9% from the same period last year, reflecting a focus on efficiency. Management raised full‑year 2025 guidance, projecting net sales of $3.06 billion to $3.07 billion and adjusted diluted EPS of $6.15 to $6.35. The company also issued a fourth‑quarter guidance range of $790 million to $800 million in net sales and $1.81 to $1.86 in adjusted EPS, signaling continued strength in its high‑value product portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.